Lipoproteína(a)
Grupo Argentino Estudio Lipoproteína (a)
.png)
Novedades Marzo 2026
PLoS One. 2026 Feb 23;21(2):e0342704. doi: 10.1371/journal.pone.0342704. eCollection 2026.
Autores:
Mengru Wang 1 , Fudong Hu 2 , Rongyan Jiang 1 , Sheng Tu 1
Conclusión: The Lp(a)-CatLet© synergy enhances MACCE risk stratification in ePCI-treated AMI, reflecting complementary pathobiological (Lp(a)-driven plaque vulnerability) and anatomical (CatLet©-quantified complexity) pathways. This dual-parameter approach could support post-PCI risk stratification and follow-up planning.
Cardiol J. 2026:33:e00226010. doi: 10.5603/cj.108082. Epub 2025 Oct 16.
Autores:
Tomasz Saniewski 1 2 , Grzegorz Procyk 3 4 , Jakub Zimodro 3 4 , Olivia Wasilewska 5 , Bartosz Mroczyk 5 , Michał Lis 5 6 , Aleksandra Gąsecka 3
Conclusión: High Lp(a) is prevalent in the Polish population, and thus it is important to measure it routinely in each individual at least once in a lifetime and control all other known cardiovascular risk factors to decrease the overall risk.
Georgian Med News. 2025 Dec:(369):120-126.
Autores:
G Derbissalina 1 , Z Bekbergenova 1 , A Umbetzhanova 1 , G Mauletbayeva 1 , G Bedelbayeva 2
Conclusión: Comprehensive assessment of anthropometric and biochemical biomarkers may be useful for early cardiovascular risk stratification in patients with arterial hypertension in Kazakhstan. The observed tendencies highlight potential region-specific features of cardiometabolic risk, warranting further investigation in larger cohorts.
Int J Mol Sci. 2026 Jan 23;27(3):1160. doi: 10.3390/ijms27031160.
Autores:
Agnė Liuizė Abramavičiūtė 1 , Jolanta Laukaitienė 1 , Renata Paukštaitienė 2 , Viltė Marija Gintauskienė 3 , Aušra Mongirdienė 1
JAMA Cardiol. 2026 Feb 1;11(2):175-185. doi: 10.1001/jamacardio.2025.5043.
Autores:
Ask Tybjærg Nordestgaard 1 2 , Daniel I Chasman 1 3 , Vinayaga Moorthy 1 , Jordan M Kraaijenhof 4 , Nancy R Cook 1 3 , I-Min Lee 1 3 , Julie E Buring 1 3 , Paul M Ridker 1 3 5
Conclusión y Relevancia: Per the results of this cohort study, very high lipoprotein(a) levels correlated with increased 30-year risk of cardiovascular disease among healthy women. Screening for elevated lipoprotein(a) in the general population may be warranted.
Eur Heart J Cardiovasc Imaging. 2026 Feb 9;27(2):264-273. doi: 10.1093/ehjci/jeaf320.
Autores:
Marin Boute 1 2 , Paul Salembier 1 2 , Anne-Catherine Pouleur 1 2 , Agnès Pasquet 1 2 , Bernhard L Gerber 1 2 , David De Azevedo 1 2 , Damien Gruson 2 3 , Laurent de Kerchove 2 4 , Joelle Kefer 1 2 , Christophe Beauloye 1 2 5 , Sandrine Horman 2 , Frédéric Maes 1 2 , Sophie Pierard 1 2 5 , David Vancraeynest 1 2
Conclusión: Elevated Lp(a) is independently associated with long-term risk of stenotic/mixed SVD. These findings highlight Lp(a) as a promising biomarker of prosthetic valve vulnerability and support investigation of emerging Lp(a)-lowering therapies to improve valve durability.
J Card Fail. 2026 Feb;32(2):382-390. doi: 10.1016/j.cardfail.2025.03.016. Epub 2025 Apr 4.
Autores:
Adithya K Yadalam 1 , Apoorva Gangavelli 2 , Alexander C Razavi 1 , Yi-An Ko 3 , Ayman Alkhoder 1 , Nisreen Haroun 1 , Rafia Lodhi 1 , Ahmed Eldaidamouni 1 , Mahmoud Al Kasem 1 , Arshed A Quyyumi 4
Conclusión: In patients with HF, Lp(a) ≥30 mg/dL independently predicts the risk of cardiovascular death or HF hospitalization.
J Am Heart Assoc. 2026 Feb 17;15(4):e042361. doi: 10.1161/JAHA.125.042361. Epub 2026 Feb 11.
Autores:
Richard Kazibwe 1 , Christopher L Schaich 2 , Parag A Chevli 3 , Jeff A Kingsley 3 , Saeid Mirzai 3 , Juliana H Namutebi 4 , Muhammad Imtiaz Ahmad 5 , Anurag Mehta 6 , Harpreet S Bhatia 7 , Mitchell Paukner 8 , Rishi Rikhi 9 , Erin D Michos 10 , Michael D Shapiro 11
Conclusión: Lp(a) and IR each independently contribute to cardiovascular risk, with a combination offering improved risk stratification. This suggests that accounting for IR may enhance the assessment of Lp(a)-associated risk in the context of primary CVD prevention setting.
Turk Kardiyol Dern Ars. 2026 Feb 20;54(2):101-108. doi: 10.5543/tkda.2026.07748. Epub 2026 Jan 23.
Autores:
Ece Yurtseven 1 , Dilek Ural 1 , Gizem Yaşa 2 , Berk Kabadayı 2 , Özgür Özdemir 2 , Erol Gürsoy 1 , Saide Aytekin 1 , Vedat Aytekin 1 , Meral Kayikcioglu 3
Conclusión: In statin-naïve elderly individuals with elevated LDL-C levels, male sex, cumulative LDL-C exposure, and high Lp(a) levels were independently associated with CAD. These findings underscore the potential utility of incorporating cumulative LDL-C and Lp(a) into risk stratification for older adults.
Eur J Prev Cardiol. 2026 Feb 18;33(3):352-360. doi: 10.1093/eurjpc/zwae371.
Autores:
Martin Bird 1 , Antoine Rimbert 2 , Alan Michael Pittman 3 , Steve Eric Humphries 4 , Marta Futema 1 4
Conclusión: This genome-wide analysis of monogenic and polygenic FH causes confirms a complex and heterogeneous architecture of hypercholesterolaemia, with the LPA gene playing a significant role. Both Lp(a) and LDL-C should be measured for precision FH diagnosis. Specific therapies to lower Lp(a) should be targeted to those who will benefit most.